These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 9254992)
1. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity. Dana R; Kachhwaha VS Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992 [TBL] [Abstract][Full Text] [Related]
2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883 [TBL] [Abstract][Full Text] [Related]
3. [Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 Study Group]. Yoshizawa H; Suzuki E; Arakawa M Gan To Kagaku Ryoho; 1998 Nov; 25(13):2085-94. PubMed ID: 9838911 [TBL] [Abstract][Full Text] [Related]
4. Methods of reduction of cisplatin nephrotoxicity. Walker EM; Gale GR Ann Clin Lab Sci; 1981; 11(5):397-410. PubMed ID: 6277229 [TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Cornelison TL; Reed E Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728 [TBL] [Abstract][Full Text] [Related]
6. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070 [TBL] [Abstract][Full Text] [Related]
7. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Morgan KP; Buie LW; Savage SW Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599 [TBL] [Abstract][Full Text] [Related]
8. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial. Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529 [TBL] [Abstract][Full Text] [Related]
9. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. Leu L; Baribeault D J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050 [TBL] [Abstract][Full Text] [Related]
10. A short outpatient hydration schedule for cisplatin administration. Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783 [TBL] [Abstract][Full Text] [Related]
11. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789 [TBL] [Abstract][Full Text] [Related]
12. [Administration of high doses of cisplatin in 20-minute infusions]. Cirera L; Gay M; Tomé T; Martí M; Huguet J; Plá R Rev Clin Esp; 1988 Mar; 182(4):192-5. PubMed ID: 3137644 [No Abstract] [Full Text] [Related]
13. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis. Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808 [TBL] [Abstract][Full Text] [Related]
14. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583 [TBL] [Abstract][Full Text] [Related]
15. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity. Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773 [TBL] [Abstract][Full Text] [Related]
16. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698 [TBL] [Abstract][Full Text] [Related]
17. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion]. Izumi T Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030 [TBL] [Abstract][Full Text] [Related]
18. [Protecting kidneys from radiocontrast toxicity--do fluids or drugs help?]. Aitio ML Duodecim; 1999; 115(19):2075-84. PubMed ID: 11941801 [No Abstract] [Full Text] [Related]
19. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit. Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556 [TBL] [Abstract][Full Text] [Related]
20. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Ali BH; Al Moundhri MS Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]